Cellular Biomedicine Group, Inc. Featured on Wide World of Stocks Television
May 12 2015 - 09:30AM
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the
"Company"), a biomedicine firm engaged in the development of
effective stem cell therapies for degenerative diseases and
immunotherapies for cancer, today announced that an interview with
Tony (Bizuo) Liu, Chief Financial Officer of Cellular Biomedicine
Group, will be broadcast on Wide World of Stocks on Wednesday, May
13, 5:00 p.m. and 6:00 p.m. EDT into more than 50 million homes
nationwide over BizTV, BizTV Radio, and YouTOO America Networks.
In the interview, Mr. Liu discusses the positive interim data
from the Company's Phase IIb clinical trial for Rejoin™ human
adipose-derived mesenchymal progenitor cell (haMPC) regenerative
therapy for Knee Osteoarthritis (KOA), and the progress of its
Phase I trials of Chimeric Antigen Receptor T-Cell (CAR-T)
immuno-oncology for patients with advanced stage cancer. "It was a
pleasure to discuss Cellular Biomedicine Group's strategic
initiatives that will further validate our vision of becoming an
innovative cell-therapy company that delivers value to our
shareholders and that will serve urgent unmet medical needs in
China," said Mr. Liu.
WWOS' interview with Cellular Biomedicine Group can be seen
nationwide on Wednesday, May 13 on BizTv at 5:00pm EDT and on
YouTOO America (formally America One Network) at 6:00pm EDT.
Find us in your market: http://www.filmon.com/channel/biztv
http://www.americaone.com/watch/ https://www.youtoo.com/ Wide World
of Stocks YouTube
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of certain degenerative diseases and
cancers. Our developmental stem cell, progenitor cell, and immune
cell projects are the result of research and development by
scientists and doctors from China and the United
States. Our flagship GMP facility, consisting of eight independent
cell production lines, is designed, certified and managed according
to U.S. standards. To learn more about CBMG, please visit:
www.cellbiomedgroup.com
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include, but are not
limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2023 to Mar 2024